



[도1]




[도2]

림프절(Lymph nodes)


- 암 특이적 naïve T 세포 증가
- Treg 기능 감소




[도3]




[도4]




[圖5]



[圖6]




[도7]




[도8]


Analytical size exclusion chromatography (SEC)




[도9]




[도10]




[圖11]




[圖12]




[圖13]




[圖14]




[도15]



[도16]




[도17]




Analyte	K_D (M)	K_{on} (1/Ms)	K_{dis} (1/s)
Gl101	3.46E-08	7.0E+04	2.42E-03

[도18]




Analyte	K_D (M)	K_{on} (1/Ms)	K_{dis} (1/s)
PD-1	1.13E-07	2.72E+04	3.07E-03


[도 19]




[도 20]




[圖21]




[5:22]




[圖23]




[도24]




[도25]



[도26]




[도27]



WO 2021/187922


PCT/KR2021/003375

[도28]




Kon	Koff	Kd
1.30×10^5	2.01×10^{-3}	1.55×10^{-8}

[도29]




Kon	Koff	Kd
1.32×10^5	3.11×10^{-3}	2.36×10^{-8}

[도30]




Kon	Koff	Kd
1.10×10^5	1.27×10^{-3}	1.15×10^{-8}


[531]




[도 32]




[E33]




[도 34]




[도35]




[도36]




[도37]




[도38]




[도39]




[도 40]




[도41]




[도42]




[圖43]




[圖44]




[도45]




[도46]




[도 47]




[도48]




[도49]




[도50]



[도51]




[도52]




[도53]

IFN-gamma expressing T cell was increased after GI-101 treatment
But, not increased regulatory T cell population in tumor




[도54]




[55]


Dendritic cell population and antigen presentation effects were increased after GI-101 treatment (LLC2)




[56]



[57]




[58]




[59]


Tumor Growth Inhibition




[圖60]




[圖61]




[562]




[도63]




[도64]




[도65]




[도66]

hGI-101 (6 mpk) + Keytruda (5 mpk)


[도67]




[도68]




[도 69]




[E70]

hlgG4 (4 mpk)


[E71]

mG-101 (6 mpk)


[E72]

aPD-1 (5 mpk)


[圖73]

mGI-101 (0.6 mpk) + aPD-1 (5 mpk)


[圖74]

GI101 (0.6 mpk) + aPD-1(5 mpk)


[도75]



[도76]




[도77]



**** A significant difference at $p < 0.001$ / $p < 0.01$ / $p < 0.05$ level compared to the Vehicle


[도78]




WO 2021/187922

PCT/KR2021/003375


[도 79]




[圖80]




[圖81]



[도 82]



[83]




****/* A significant difference at $p < 0.0001/p < 0.01/p < 0.05$ level compared to the Vehicle


A significant difference at $p < 0.0001/p < 0.001/p < 0.01$ level compared to the mGI-101

\$\$ A significant difference at $p < 0.01$ level compared to the axitinib


[84]



[도85]




[도86]




Timeline diagram showing the administration of mGI-101 and Lenvatinib. mGI-101 is administered intravenously (I.V.) at days 1, 8, and 15. Lenvatinib is administered orally (P.O.) daily from day 1 to day 21.


[도87]




[도 88]




[도89]




[도90]




[도91]




[Figure 92]




[Figure 93]




[도94]




[도95]




[도96]




[도97]




[도98]




[도 99]




[5100]




[5101]




[Figure 102]




[圖103]




[圖104]




[도105]




[圖106]




[圖107]



[圖108]




[도109]




[E110]


TC1 lung cancer model for maintenance therapy




[511]




[도 112]




[도113]




[도114]




[도115]




[E116]



[E117]




[도118]




- ▶ Control (n=13)
- ▶ [CDDP + Pemetrexed + aPD-1] → [Pemetrexed + aPD-1] (n=13)
- ▶ [CDDP + Pemetrexed + aPD-1] → [Pemetrexed + aPD-1 + mGI101] (n=19)
- ▶ [CDDP + Pemetrexed + aPD-1] → [mGI101] (n=13)
- ▶ [CDDP + Pemetrexed + aPD-1 + mGI101] → [Pemetrexed + aPD-1 + mGI101] (n=15)


[도119]





[도 120]




[圖121]




[5122]




[圖123]




[圖124]




[圖125]




[Figure 126]




[Figure 127]




[Figure 128]




[圖129]




[도130]



[도131]



[도132]



[E133]

mGI-101 + STING agonist